Valuation: Scancell Holdings plc

Market Cap 113M 151M 135M 125M 212M 14.25B 215M 1.49B 586M 7.49B 566M 555M 23.87B P/E 2026
-8.09x
P/E 2027 * -3.75x
Enterprise Value 123M 165M 147M 136M 232M 15.57B 235M 1.63B 640M 8.18B 619M 606M 26.07B EV / Sales 2026
-
EV / Sales 2027 * 59.9x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 day-3.01%
1 week-3.53%
Current month-4.04%
1 month-7.96%
3 months-33.19%
6 months-31.92%
Current year-8.89%
1 week 89.5
Extreme 89.5
95
1 month 89.5
Extreme 89.5
99
Current year 89.5
Extreme 89.5
295
1 year 89.5
Extreme 89.5
295
3 years 72.6
Extreme 72.6
295
5 years 72.6
Extreme 72.6
295
10 years 1.12
Extreme 1.118
295
Manager TitleAgeSince
Chief Executive Officer 69 27/07/2021
Chief Executive Officer 64 17/11/2024
Director of Finance/CFO 50 23/04/2026
Director TitleAgeSince
Director/Board Member 69 16/11/2010
Director/Board Member 74 22/10/2019
Director/Board Member 64 23/09/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/09/25
Vulpes Investment Management Pte Ltd.
BuyCompany 3,150,000 0.3038%
08/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 102,236 0.0099%
04/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 4,400,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
-3.01%-3.53%-5.55%-34.40% 151M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+6.53%+11.68%+90.35% 52.92B
+0.82%+5.41%+8.05%+74.45% 54.82B
+2.48%+4.99%+25.79%+49.73% 44.09B
+0.64%+10.39%+22.89%+129.95% 43.72B
-1.01%+1.14%+265.92%+966.36% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+5.60%+36.60%+26.39% 23.37B
Average -0.13%+4.25%+46.89%+144.35% 38.76B
Weighted average by Cap. +0.22%+4.67%+51.76%+168.14%

Financials

2026 2027 *
Net sales 1.25M 1.67M 1.49M 1.38M 2.36M 158M 2.38M 16.56M 6.5M 83.05M 6.28M 6.15M 265M 2.31M 3.09M 2.75M 2.55M 4.35M 292M 4.4M 30.58M 12M 153M 11.6M 11.35M 489M
Net income -19.23M -25.76M -22.96M -21.25M -36.24M -2.43B -36.67M -255M -99.99M -1.28B -96.64M -94.63M -4.07B -27.94M -37.42M -33.35M -30.88M -52.64M -3.53B -53.27M -370M -145M -1.86B -140M -137M -5.92B
Net Debt 10.42M 13.95M 12.43M 11.51M 19.63M 1.32B 19.86M 138M 54.15M 692M 52.34M 51.25M 2.21B 25.57M 34.25M 30.52M 28.26M 48.18M 3.23B 48.75M 339M 133M 1.7B 128M 126M 5.41B
Projected Income Statement - Annual - Scancell Holdings plc
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
55
Date Price Change Volume
21/10/26 GBX 90.20 -3.01% 87,877
20/10/26 GBX 93.00 0.00% 150,872
19/10/26 GBX 93.00 0.00% 82,543
16/10/26 GBX 93.00 -0.53% 27,870
15/10/26 GBX 93.50 0.00% 61,639
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9300GBP
Average target price
1.900GBP
Spread / Average Target
+104.30%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Scancell Holdings plc
  1. Stock Market
  2. Stocks
  3. SCLP Stock